A carregar...
Publicação
Macular OCT findings in ROP patients treated with both laser and bevacizumab
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.27 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Objective: To describe macular optical coherence tomography (OCT) findings in children with
history of retinopathy of prematurity (ROP) treated with both laser and bevacizumab.
Methods: Clinical records and OCT (Stratus OCTTM Carl Zeiss Meditec) findings of the first 3 patients
treated with both laser and bevacizumab at our hospital were reviewed. Control group were
patients who only had laser treatment. One eye from each patient was randomly chosen. The main
outcome measure was foveal and parafoveal retinal thickness.
Results: 7 eyes of 7 patients with type 1 (stage 3+) disease were studied. All eyes were submited to
laser ablation of peripheral retina. The bevacizumab group (3 patients) recieved secondary intravitreal
injection (0.03mL 25mg/mL). On the bevacizumab group, at three years of age, mean
parafoveal retinal thickness was 219μm, mean foveal thickness was 208μm, with mean foveal
depression of 11μm. On the control group (4 patients), aged between five and six years of age,
mean parafoveal retinal thickness was 256μm, mean foveal thickness was 243μm, with mean
foveal depression of 13μm. The Wilcoxon rank-sum test showed no statistical difference between
both groups.
Conclusions: recent studies in the literature have shown a reduced foveal depression in premature
infants with or whithout ROP comparing with normal full-term children. We report the same
findings in this series of children treated with both laser and bevacizumab.
Descrição
Palavras-chave
Retinopatia da prematuridade Criança Bevacizumab Optical coherence tomography Retinopathy of prematurity Child Foveal thickness
Contexto Educativo
Citação
WORLD CONGRESS ON RETINOPATHY OF PREMATURITY, 3, Shangai, 14-16 October 2012